Titan Pharmaceuticals, citing "significant" safety concerns, halted the trial of an experimental lung-cancer drug. Unspecified problems arose when treatment with the drug Pivanex was combined with the chemotherapy drug docetaxel. Titan also said it would halt mid-stage studies of the drug in chronic lymphocytic leukemia and melanoma until data from the lung cancer study is analyzed more extensively.

Full Story:

Related Summaries